-transparent.png){kind=logo}
This study evaluated the clinical efficacy and safety of a new triazolobenzodiazepine, adinazolam, and imipramine in 40 patients with carefully diagnosed major depressive disorder. Overall, adinazolam was found to be as effective as imipramine. In addition, when patients with more severe, melancholic, subtype of depression were examined, adinazolam was also as effective as imipramine. With the exception of sedation, adinazolam patients demonstrated fewer overall adverse events than imipramine subjects. These results suggest that adinazolam may represent an interesting antidepressant compound.
Related Publications
J D Amsterdam, and
M Kaplan, and
L Potter, and
L Bloom, and
K Rickels
July 1991,
Pharmacopsychiatry,
J D Amsterdam, and
M Kaplan, and
L Potter, and
L Bloom, and
K Rickels
June 1993,
Bollettino della Societa italiana di biologia sperimentale,
J D Amsterdam, and
M Kaplan, and
L Potter, and
L Bloom, and
K Rickels
November 1983,
Neuropharmacology,
J D Amsterdam, and
M Kaplan, and
L Potter, and
L Bloom, and
K Rickels
June 2003,
The Journal of clinical psychiatry,
J D Amsterdam, and
M Kaplan, and
L Potter, and
L Bloom, and
K Rickels
June 2004,
Current medical research and opinion,
J D Amsterdam, and
M Kaplan, and
L Potter, and
L Bloom, and
K Rickels
April 1993,
Acta psychiatrica Scandinavica,
J D Amsterdam, and
M Kaplan, and
L Potter, and
L Bloom, and
K Rickels
January 1986,
Psychopharmacology bulletin,
J D Amsterdam, and
M Kaplan, and
L Potter, and
L Bloom, and
K Rickels
January 2016,
Expert opinion on pharmacotherapy,
J D Amsterdam, and
M Kaplan, and
L Potter, and
L Bloom, and
K Rickels
October 1983,
Acta psychiatrica Scandinavica,
J D Amsterdam, and
M Kaplan, and
L Potter, and
L Bloom, and
K Rickels
January 2002,
Journal of psychiatric research,
